A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease.

MLA

Laderach, Diego J., et al. “A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease.” Cancer Research, vol. 73, no. 1, Jan. 2013, pp. 86–96. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-12-1260.

APA

Laderach, D. J., Gentilini, L. D., Giribaldi, L., Delgado, V. C., Nugnes, L., Croci, D. O., Nakouzi, N. A., Sacca, P., Casas, G., Mazza, O., Shipp, M. A., Vazquez, E., Chauchereau, A., Kutok, J. L., Rodig, S. J., Elola, M. T., Compagno, D., & Rabinovich, G. A. (2013). A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. Cancer Research, 73(1), 86–96. https://doi.org/10.1158/0008-5472.CAN-12-1260

Chicago

Laderach, Diego J., Lucas D. Gentilini, Laura Giribaldi, Victor Cardenas Delgado, Lorena Nugnes, Diego O. Croci, Nader Al Nakouzi, et al. 2013. “A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease.” Cancer Research 73 (1): 86–96. doi:10.1158/0008-5472.CAN-12-1260.